Literature DB >> 11953332

New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.

M Campieri1.   

Abstract

Although new salicylates are now available for the treatment of ulcerative colitis, sulphasazaline still has an important therapeutic role. The role of salicylates in Crohn's disease is limited to the mild activity phase; further data are required to clarify its role in maintenance on remission. New steroids are a real alternative to traditional steroids in active ulcerative colitis and Crohn's disease.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11953332      PMCID： PMC1867683          DOI： 10.1136/gut.50.suppl_3.iii43

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  36 in total

1.  Mesalamine and relapse prevention in Crohn's disease.

Authors:  M Cottone; C Cammà
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.

Authors:  H Lochs; M Mayer; W E Fleig; P B Mortensen; P Bauer; D Genser; W Petritsch; M Raithel; R Hoffmann; V Gross; M Plauth; M Staun; L B Nesje
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

3.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.

Authors:  M Safdi; M DeMicco; C Sninsky; P Banks; L Wruble; J Deren; G Koval; T Nichols; S Targan; C Fleishman; B Wiita
Journal:  Am J Gastroenterol       Date:  1997-10       Impact factor: 10.864

Review 4.  Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.

Authors:  J K Marshall; E J Irvine
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

5.  A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.

Authors:  R D Cohen; D M Woseth; R A Thisted; S B Hanauer
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

6.  Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.

Authors:  J R Green; A J Lobo; C D Holdsworth; R J Leicester; J A Gibson; G D Kerr; H J Hodgson; K J Parkins; M D Taylor
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

7.  Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.

Authors:  J R Green; J A Gibson; G D Kerr; E T Swarbrick; A J Lobo; C D Holdsworth; J P Crowe; K J Schofield; M D Taylor
Journal:  Aliment Pharmacol Ther       Date:  1998-12       Impact factor: 8.171

8.  Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis.

Authors:  M Campieri; M Cottone; F Miglio; F Manenti; M Astegiano; A D'Arienzo; F Manguso; G D'Albasio; A Bonanomi; R Galeazzi; A Orlando; G N Castiglione; P Gionchetti
Journal:  Aliment Pharmacol Ther       Date:  1998-04       Impact factor: 8.171

9.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

10.  Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group.

Authors:  G Hellers; A Cortot; D Jewell; C E Leijonmarck; R Löfberg; H Malchow; L G Nilsson; F Pallone; S Pena; T Persson; C Prantera; P Rutgeerts
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682
View more
  8 in total

1.  Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations.

Authors:  Gregory C A Amos; Chrysi Sergaki; Alastair Logan; Rolland Iriarte; Ayman Bannaga; Subashini Chandrapalan; Elizabeth M H Wellington; Sjoerd Rijpkema; Ramesh P Arasaradnam
Journal:  Sci Rep       Date:  2021-09-21       Impact factor: 4.996

2.  Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization.

Authors:  H Herfarth; V Gross; T Andus; I Caesar; H Vogelsang; G Adler; H Malchow; A Petri; M Gierend; J Schölmerich
Journal:  Int J Colorectal Dis       Date:  2003-09-09       Impact factor: 2.571

3.  Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.

Authors:  Jin Li; Cheng Chen; Xiao-Nian Cao; Gui-Hua Wang; Jun-Bo Hu; Jing Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-02-06

4.  Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.

Authors:  Cosimo Prantera; Stefano Marconi
Journal:  Therap Adv Gastroenterol       Date:  2013-03       Impact factor: 4.409

5.  Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa.

Authors:  Efrat Harel; Abraham Rubinstein; Aviram Nissan; Elena Khazanov; Mirela Nadler Milbauer; Yechezkel Barenholz; Boaz Tirosh
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

6.  Rhinosinusitis derived Staphylococcal enterotoxin B possibly associates with pathogenesis of ulcerative colitis.

Authors:  Ping-Chang Yang; Tao Liu; Bin-Quan Wang; Tao-Yuan Zhang; Zi-Yuan An; Peng-Yuan Zheng; Dao-Fa Tian
Journal:  BMC Gastroenterol       Date:  2005-09-06       Impact factor: 3.067

7.  Uygur medicine Xipayi Kui Jie'an affects gene expression profiles in intestinal tissue lesions in a rat model of ulcerative colitis.

Authors:  Kurexi Yunusi; Jingping Zhang; Li Zhong; Gulinisha Mosha; Ajiguli Nuermaimaiti; Mairipaiti Abudula; Halmurat Upur
Journal:  BMC Complement Altern Med       Date:  2015-05-22       Impact factor: 3.659

8.  An observational study of the use of beclomethasone dipropionate suppositories in the treatment of lower urinary tract inflammation in men.

Authors:  Giorgio Bozzini; Marco Provenzano; Nicolò Buffi; Mauro Seveso; Giovanni Lughezzani; Giorgio Guazzoni; Alberto Mandressi; Gianluigi Taverna
Journal:  BMC Urol       Date:  2016-06-08       Impact factor: 2.264
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.